The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $30 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $30 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
A phase II clinical trial has launched to study Lutathera® in adolescents with gastroenterpancreatic neuroendocrine tumors (GEP-NET), pheochromocyomas and paragangliomas (PPGLs).
The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD
As another summer came to a close, the riders of Biking for Debbie were on the road again!
One hundred friends and relatives gathered to celebrate Nathan Montoya’s life on July 24, 2021, which would have been his 43rd birthday.
Dr. Po Hien Ear’s research involves growing NET spheroid clusters in large enough numbers to be used to screen the potential anti-tumor properties of hundreds of therapeutic compounds.
A phase II clinical trial has opened to investigate the safety and effectiveness of the drug belzutifan for pancreatic neuroendocrine tumors (pNETs) and pheochromocytoma/paraganglioma (PPGL).
Etay Ziv, MD, PhD, an interventional radiologist at Memorial Sloan Kettering Cancer Center in New York, leads a translational research study, funded by NETRF through the American Association for Cancer Research, that aims to understand the process of how pancreatic NETs progress from low grade to higher, more aggressive grade tumors.
Doctors at University of California San Francisco (UCSF) are conducting the first-of-its-kind e-NET study to learn about symptoms and quality of life for patients with neuroendocrine cancer. This is your chance to become a citizen scientist and help the researchers learn more about NETs.
A Family Takes Steps to Honor the Memory of their Loved One Judith Jones loved Nantucket. From the first time she visited the island off
